April 17 (Reuters) - The U.S. Food and Drug Administration has approved Gamida Cell Ltd's blood cancer therapy, Omisirge, the health regulator said on Monday. (Reporting by Pratik Jain in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.017 USD | +2.41% | 0.00% | -95.88% |
23/05 | Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
10/04 | Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
-95.88% | 26.19L | |
+9.83% | 12TCr | |
+10.80% | 11TCr | |
-10.84% | 2.34TCr | |
-1.69% | 2.21TCr | |
-10.23% | 1.83TCr | |
-41.92% | 1.66TCr | |
-15.11% | 1.6TCr | |
+6.62% | 1.4TCr | |
+17.53% | 1.17TCr |
- Stock Market
- Equities
- GMDA Stock
- News Gamida Cell Ltd.
- US FDA approves Gamida's blood cancer therapy